MARKET

BFRIW

BFRIW

Biofrontera
NASDAQ
0.0570
+0.0017
+3.07%
Closed 11:45 04/02 EDT
OPEN
0.0574
PREV CLOSE
0.0553
HIGH
0.0574
LOW
0.0561
VOLUME
2.73K
TURNOVER
0
52 WEEK HIGH
0.2770
52 WEEK LOW
0.0251
MARKET CAP
--
P/E (TTM)
-0.0550
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BFRI last week (0323-0327)?
Weekly Report · 6d ago
Weekly Report: what happened at BFRI last week (0316-0320)?
Weekly Report · 03/23 10:37
Roth MKM Reaffirms Their Buy Rating on Biofrontera (BFRI)
TipRanks · 03/20 13:17
Biofrontera Earnings Call: Profits Rise, Risks Remain
TipRanks · 03/20 00:09
Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate
Benzinga · 03/19 21:49
Biofrontera reports rise in Q4 revenue, turns profitable
Seeking Alpha · 03/19 19:18
Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition
Seeking Alpha · 03/19 19:12
Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength
Reuters · 03/19 13:36
More
About BFRIW
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Webull offers Biofrontera Inc stock information, including NASDAQ: BFRIW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRIW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BFRIW stock methods without spending real money on the virtual paper trading platform.